FDA accepts Sucampo’s lubiprostone sNDA for review
This article was originally published in Pharmaceutical Approvals Monthly
FDA has accepted Sucampo's supplemental NDA for lubiprostone (8 mcg) for the treatment of irritable bowel syndrome with constipation. A standard 10-month review would set the clock for an April 29, 2008, user fee date. The sNDA is supported by two Phase III double-blinded, randomized, placebo-controlled trials involving 1,171 adults, followed by one long-term open-label safety and efficacy extension trial involving 522 adults diagnosed with IBS-C. Marketed by Sucampo and Takeda as Amitiza in a higher dosage form (24 mcg), lubiprostone was approved in January 2006 for the treatment of chronic idiopathic constipation in adults...
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.